Clinical trials: Gout Attack

Gout Attack

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack

• Terminated
• Age: 18 to 80 years
• Phase 2
• Pill or oral medicine
• Injection or infusion
• Results posted

The primary goal of the study was to evaluate the parameters of efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of RPH-104 in adult patients with acute gout attack.

Trial name

NCT04067492

Testing

RPH - 104, Voltaren®

Where

11 sites in Russia

Volunteers

47 people

Sponsor

R-Pharm